Literature DB >> 28943931

A missing link between RON expression and oncological outcomes in resected left-sided pancreatic cancer.

Dai Hoon Han1, Chang Moo Kang1, Sung Whan Lee1, Ho Kyoung Hwang1, Woo Jung Lee1.   

Abstract

Alteration and activation of recepteur d'origine nantais (RON) expression is known to be associated with cancer progression and decreased survival in various types of human cancer, including pancreatic cancer. Therefore, in the present study, RON expression levels were determined in resected left-sided pancreatic cancer to evaluate the potential oncological role of RON in the clinical setting of distal pancreatic cancer. From January 2005 to December 2011, a total of 57 patients underwent radical distal pancreatectomy for left-sided pancreatic cancer. Ductal adenocarcinoma was confirmed in all patients. Among these patients, 17 patients who received preoperative neoadjuvant treatment and 7 patients without available paraffin-embedded tissue blocks were excluded from the present study. RON expression in a the pancreatic cancer cell lines ASPC-1, BxPC-3, MiaPaCa-3 and Panc-1, as well as in resected left-sided pancreatic cancer specimens was determined by Western blot analysis. RON and vascular endothelial growth factor (VEGF) overexpression in resected left-sided pancreatic cancer was also evaluated by immunohistochemistry using pre-diluted anti-RON and anti-VEGF antibodies. An association was identified between the oncological outcome and RON overexpression. Increased levels of RON expression were observed in two pancreatic cancer cell lines, AsPC-1 and BxPC-3. RON overexpression was detected in specimens from 15/33 patients (45.5%) using immunohistochemistry. No significant association was identified between RON overexpression and VEGF overexpression (25.5 vs. 87.9%; P=0.667). No significant differences in disease-free survival or disease-specific survival associated with RON overexpression were identified. Although the results of previous studies have suggested that RON is a potential target for the treatment of pancreatic cancer, in the present study no association between RON overexpression and any adverse oncological effect was identified.

Entities:  

Keywords:  pancreatic cancer; prognosis; recepteur d'origine nantais

Year:  2017        PMID: 28943931      PMCID: PMC5604100          DOI: 10.3892/ol.2017.6696

Source DB:  PubMed          Journal:  Oncol Lett        ISSN: 1792-1074            Impact factor:   2.967


  36 in total

Review 1.  EMT: when epithelial cells decide to become mesenchymal-like cells.

Authors:  Raghu Kalluri
Journal:  J Clin Invest       Date:  2009-06       Impact factor: 14.808

2.  The RON tyrosine kinase receptor regulates vascular endothelial growth factor production in pancreatic cancer cells.

Authors:  Ryan M Thomas; Dawn V Jaquish; Randall P French; Andrew M Lowy
Journal:  Pancreas       Date:  2010-04       Impact factor: 3.327

3.  Prognostic significance of co-expression of RON and MET receptors in node-negative breast cancer patients.

Authors:  Wen-Ying Lee; Helen H W Chen; Nan-Haw Chow; Wu-Chou Su; Pin-Wen Lin; How-Ran Guo
Journal:  Clin Cancer Res       Date:  2005-03-15       Impact factor: 12.531

4.  Identification of a novel splicing product of the RON receptor tyrosine kinase in human colorectal carcinoma cells.

Authors:  M H Wang; A L Kurtz; Y Chen
Journal:  Carcinogenesis       Date:  2000-08       Impact factor: 4.944

5.  Identification of the ron gene product as the receptor for the human macrophage stimulating protein.

Authors:  M H Wang; C Ronsin; M C Gesnel; L Coupey; A Skeel; E J Leonard; R Breathnach
Journal:  Science       Date:  1994-10-07       Impact factor: 47.728

Review 6.  The basics of epithelial-mesenchymal transition.

Authors:  Raghu Kalluri; Robert A Weinberg
Journal:  J Clin Invest       Date:  2009-06       Impact factor: 14.808

7.  The RON receptor tyrosine kinase mediates oncogenic phenotypes in pancreatic cancer cells and is increasingly expressed during pancreatic cancer progression.

Authors:  Ryan M Thomas; Kenya Toney; Cecilia Fenoglio-Preiser; Monica P Revelo-Penafiel; Sunil R Hingorani; David A Tuveson; Susan E Waltz; Andrew M Lowy
Journal:  Cancer Res       Date:  2007-07-01       Impact factor: 12.701

8.  Distinct populations of cancer stem cells determine tumor growth and metastatic activity in human pancreatic cancer.

Authors:  Patrick C Hermann; Stephan L Huber; Tanja Herrler; Alexandra Aicher; Joachim W Ellwart; Markus Guba; Christiane J Bruns; Christopher Heeschen
Journal:  Cell Stem Cell       Date:  2007-09-13       Impact factor: 24.633

9.  RON receptor tyrosine kinase as a target for delivery of chemodrugs by antibody directed pathway for cancer cell cytotoxicity.

Authors:  Sunny Guin; Hang-Ping Yao; Ming-Hai Wang
Journal:  Mol Pharm       Date:  2010-04-05       Impact factor: 4.939

10.  A novel protein isoform of the RON tyrosine kinase receptor transforms human pancreatic duct epithelial cells.

Authors:  J Chakedis; R French; M Babicky; D Jaquish; H Howard; E Mose; R Lam; P Holman; J Miyamoto; Z Walterscheid; A M Lowy
Journal:  Oncogene       Date:  2015-10-19       Impact factor: 9.867

View more
  1 in total

1.  Short-form RON (sf-RON) enhances glucose metabolism to promote cell proliferation via activating β-catenin/SIX1 signaling pathway in gastric cancer.

Authors:  Ziliang Wang; Yufei Yang; Shuang Hu; Jian He; Zheng Wu; Zihao Qi; Mingzhu Huang; Rujiao Liu; Ying Lin; Cong Tan; Midie Xu; Zhe Zhang
Journal:  Cell Biol Toxicol       Date:  2020-05-12       Impact factor: 6.691

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.